Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Get Free Report) major shareholder Braden Michael Leonard bought 55,300 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were acquired at an average price of $1.36 per share, for a total transaction of $75,208.00. Following the completion of the purchase, the insider now owns 3,358,243 shares in the company, valued at approximately $4,567,210.48. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Braden Michael Leonard also recently made the following trade(s):
- On Tuesday, August 13th, Braden Michael Leonard purchased 171,339 shares of Reneo Pharmaceuticals stock. The shares were acquired at an average cost of $1.39 per share, for a total transaction of $238,161.21.
Reneo Pharmaceuticals Stock Down 2.7 %
RPHM traded down $0.04 during midday trading on Thursday, hitting $1.46. 194,899 shares of the company traded hands, compared to its average volume of 241,945. The company’s 50-day moving average is $1.47 and its 200 day moving average is $1.60. The firm has a market capitalization of $48.81 million, a PE ratio of -0.69 and a beta of 0.19. Reneo Pharmaceuticals, Inc. has a 52 week low of $0.98 and a 52 week high of $9.21.
Hedge Funds Weigh In On Reneo Pharmaceuticals
Hedge funds and other institutional investors have recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Reneo Pharmaceuticals during the 2nd quarter worth $27,000. Jump Financial LLC purchased a new stake in Reneo Pharmaceuticals in the fourth quarter worth about $41,000. Pale Fire Capital SE raised its stake in shares of Reneo Pharmaceuticals by 102.7% in the fourth quarter. Pale Fire Capital SE now owns 30,100 shares of the company’s stock worth $48,000 after buying an additional 15,249 shares during the period. Marquette Asset Management LLC bought a new position in shares of Reneo Pharmaceuticals during the 1st quarter valued at approximately $122,000. Finally, Vestal Point Capital LP purchased a new stake in Reneo Pharmaceuticals in the 4th quarter worth approximately $640,000. 90.98% of the stock is owned by institutional investors.
Reneo Pharmaceuticals Company Profile
Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
See Also
- Five stocks we like better than Reneo Pharmaceuticals
- How to Calculate Return on Investment (ROI)
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- What is MarketRank™? How to Use it
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
- 3 Best Fintech Stocks for a Portfolio Boost
- Is Alphabet a Long-Term Buying Opportunity After Recent Declines?
Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.